Design of an ideal hormone replacement therapy for women

Molecular Carcinogenesis

Volumn 17, Issue 3, 1996, Pages 108-111

  Tonetti, Debra A ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

DNA adducts; Endometrial carcinoma; Hepatocellular carcinoma; Hormone replacement therapy; Tamoxifen

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER RISK; CONFERENCE PAPER; ENDOMETRIUM CANCER; FEMALE; HORMONAL THERAPY; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

ANIMALS; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIVER NEOPLASMS; TAMOXIFEN;

EID: 0029958410     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199611)17:3<108::AID-MC1>3.3.CO;2-3     Document Type: Conference Paper

References (21)

1. Jordan VC. Studies on the estrogen receptor in breast cancer - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36:267-285, 1995.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 330:1-15, 71-85, 1992
3. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812-815, 1988.
4. Fornander T, Rutqvist LE, Cedermark BV, et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1:117-120, 1989.
5. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B- 14. J Natl Cancer Inst 80:527-537, 1994.
6. Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: Clearing up a controversy. Clin Cancer Res 1:467-472, 1995.
7. Williams GM, Iatropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317, 1993.
8. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two- year carcinogenicity study of tamoxifen in Alderley Park Wistar- derived rats. Cancer Res 53:3919-3924, 1993.
9. Han X, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360-1363, 1992.
10. Potter GA, McCague R, Jarman M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following oxidative metabolism. Carcinogenesis 15:439-442, 1994.
11. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15:2087-2094, 1994.
12. Phillips DH, Carmichael PL, Hewer A, Cole KJ, Poon GK. α- Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 54:5518-5522, 1994.
13. Pongracz K, Pathak DN, Nakamura T, Bulingame AL, Bodell WJ. Activation of the tamoxifen derivative metabolite E to form DNA adducts: Comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res 55:3012-3015, 1995.
14. Moorthy B, Sriram P, Pathak DN, Bodell WJ, Randerath K. Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res 56:53-57, 1996.
15. Osborne MR, Hewer A, Hardcastle IR, Carmichael PL, Phillips DH. Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res 56:66-71, 1996.
16. Tucker MJ, Adam HK, Patterson JS. Tamoxifen. In: Lawrence DR, McClean AEM, Wetherall M (eds), Safety Testing of New Drugs, Academic Press, London, 1984, pp. 125-161.
17. White INH, de Matteis F, Davies A, et al. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197-2203, 1992.
18. Hard GC, Iatropoulos MJ, Jordan K, et al. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53:4534-4541, 1993.
19. Jordan VC. What if tamoxifen (ICI 46,474) had been found to produce rat liver tumors in 1973? Ann Oncol 6:29-34, 1995.
20. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16:1651-1654, 1995.
21. Jordan VC. Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem Suppl 22:51-57, 1995.